Paige.AI Receives FDA's Breakthrough Designation for its Artificial Intelligence in Pathology
Shots:
- FDA grants BT designation to Paige.AI to develop AI in computational pathology for the diagnosis and treatment of cancer including prostate cancer
- The FDA’s BT designation is granted for technologies that provide effective diagnosis and treatment for life-threatening diseases
- Paige.AI is based on Fuch’s technology- works with the de-identified dataset to develop AI portfolio targeting multiple cancer across the world
Ref: Business Wire | Image: Medium
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
